FPC Welcomes FDA Approval of AbbVie’s New Pangenotypic HCV Combination Mavyret

FPC Welcomes FDA Approval of AbbVie’s New Pangenotypic HCV Combination Mavyret

Wholesale Acquisition Cost price of $26,400 for eight-week course marks significant departure from prohibitive drug prices set for first-generation cures.

NEW YORK, NY, AUGUST 4, 2017  – The Fair Pricing Coalition (FPC) today applauded U.S. Food and Drug Administration approval of the first eight-week pangenotypic, ribavirin-free, curative regimen for hepatitis C virus (HCV) infection and expressed its appreciation for a wholesale acquisition cost (WAC) that should translate into improved affordability, with fewer access restrictions, to insurers and people living with the virus.
“This is very good news for people living with HCV in the United States,” said Tim Horn, co-chair of the Fair Pricing Coalition. “The majority of people using Mavyret will be able to complete treatment in just eight weeks, compared with standard 12-week courses, depending on their treatment history and cirrhosis status.  The favorable U.S. launch price set by AbbVie should also be good news to public and private payors, resulting in fewer access barriers, a substantial increase in the number of cures, and significant progress toward HCV elimination. FPC remains committed to ensuring access the U.S. and, globally, working with its partners toward affordable pricing in low- and middle-income countries.”
Continue reading.....